Ich glaube mit dieser Aktie kann sich etwas starkes entwickeln.
Meine Meinung und keine Kaufempfehlung
Meine Meinung und keine Kaufempfehlung
Hallo Anleger
Beiträge: 6
Zugriffe: 5.508 / Heute: 1
Zugriffe: 5.508 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Japan UCITS ETF 1D
Perf. 12M: +155,87%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +68,36%
Xtrackers Artificial Intelligence and Big Data UCITS ETF 1C
Perf. 12M: +57,05%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +53,56%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +51,49%
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
07:00
Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID-19
Company Website: canfite.com
PETACH TIKVA, Israel -- (Business Wire)
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms. Through the pre-IND, Can-Fite anticipates receiving the FDA’s advice and guidance on its planned clinical study protocol. Following the FDA’s advice, Can-Fite plans to submit an IND application for Piclidenoson to be evaluated as a potential addition to the current standard of care treatment for COVID-19.
Piclidenoson, an A3 adenosine receptor (A3AR) agonist, has a well-established safety record in the U.S. and globally, and has been dosed in over 1,000 patients in clinical studies for the treatment of rheumatoid arthritis and psoriasis. The use of A3AR agonists as potent anti-inflammatory agents in addition to standard of care in acute infectious diseases where host defense responses are overwhelming, leading to cytokine storm and death, is supported by several peer reviewed studies, as well as by Can-Fite’s own work in the field of adenosine biology. A3AR agonists are effective in models of inflammation and sepsis.
“We look forward to our discussions with the FDA regarding moving forward into a clinical study of Piclidenoson for COVID-19. The literature, our experience in adenosine biology, and the favorable human safety experience of the drug support the exploration of Piclidenoson as an add-on therapy to standard of care for COVID-19 patients who are hospitalized with moderate to severe symptoms,” stated Can-Fite CEO Dr. Pnina Fishman.
07:00
Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID-19
Company Website: canfite.com
PETACH TIKVA, Israel -- (Business Wire)
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms. Through the pre-IND, Can-Fite anticipates receiving the FDA’s advice and guidance on its planned clinical study protocol. Following the FDA’s advice, Can-Fite plans to submit an IND application for Piclidenoson to be evaluated as a potential addition to the current standard of care treatment for COVID-19.
Piclidenoson, an A3 adenosine receptor (A3AR) agonist, has a well-established safety record in the U.S. and globally, and has been dosed in over 1,000 patients in clinical studies for the treatment of rheumatoid arthritis and psoriasis. The use of A3AR agonists as potent anti-inflammatory agents in addition to standard of care in acute infectious diseases where host defense responses are overwhelming, leading to cytokine storm and death, is supported by several peer reviewed studies, as well as by Can-Fite’s own work in the field of adenosine biology. A3AR agonists are effective in models of inflammation and sepsis.
“We look forward to our discussions with the FDA regarding moving forward into a clinical study of Piclidenoson for COVID-19. The literature, our experience in adenosine biology, and the favorable human safety experience of the drug support the exploration of Piclidenoson as an add-on therapy to standard of care for COVID-19 patients who are hospitalized with moderate to severe symptoms,” stated Can-Fite CEO Dr. Pnina Fishman.
VANCOUVER, British Columbia, May 15, 2020 (GLOBE NEWSWIRE) -- PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) ("Primo" or the "Company") is pleased to announce that it has received the ability to import Hand Sanitizer for the duration of the COVID-19 emergency response from the Health Products and Food Branch of Health Canada.
“This license specifically authorizes the license-holder to manufacture, package, label and/or import “antiseptic Skin Cleansers/Hand Sanitizers” as described in the Product Monograph provided by Primo Nutraceuticals Inc., to Health Canada. The following site is considered to-be-in compliance with GMP requirements outlined in PART 3 of the Natural Health Products Regulations. Activities include: Importing to Canada and Manufacturing, Packaging and Labeling from the U.S.A.”
“This license specifically authorizes the license-holder to manufacture, package, label and/or import “antiseptic Skin Cleansers/Hand Sanitizers” as described in the Product Monograph provided by Primo Nutraceuticals Inc., to Health Canada. The following site is considered to-be-in compliance with GMP requirements outlined in PART 3 of the Natural Health Products Regulations. Activities include: Importing to Canada and Manufacturing, Packaging and Labeling from the U.S.A.”
Primo Nutraceuticals Inc. Receives Approval to Sell its Hand Sanitizer on Amazon.com
Primo Nutraceuticals Inc. Signs Letter of Intent to Enter into Funding and Asset Purchase Agreement with World Agri Minerals Ltd.
Neueste Beiträge aus dem Primo Nutraceuticals Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 5 | Hallo Anleger | Zander2016 | Sommertrader1 | 03.06.20 15:12 |
